Deletion of Abi3 gene locus exacerbates neuropathological features of Alzheimer’s disease in a mouse model of Aβ amyloidosis
Open accessThe DOI matches its Crossref record; 82 of the 82 references it cites were found in a registry or an index; 67 of the 85 sources its claims cite were checked for support.
Abstract
A cytoskeleton-associated protein regulates microglial function and affects Alzheimer’s disease phenotypes.
Overview
CoChat Summary
TL;DR
Deletion of the Abi3 locus in 5XFAD mice exacerbated Aβ amyloidosis, increased amyloid plaques, reduced plaque-associated microglia, altered immune gene expression, impaired microglial migration/phagocytosis, and worsened hippocampal LTP. The findings suggest ABI3 regulates microglial function and Aβ pathology in a mouse model of Alzheimer’s disease–like amyloidosis.
Key findings
- In 8-month-old 5XFAD mice, loss of Abi3 increased cortical Aβ in a gene dose–dependent manner: insoluble Aβ40 rose 1.9- and 2.7-fold in male Abi3+/− and Abi3−/− mice versus Abi3+/+, and insoluble Aβ42 rose 1.7- and 2.3-fold; soluble Aβ40 rose 1.4- and 2.1-fold, and soluble Aβ42 rose 1.4- and 1.6-fold. Female Abi3−/− mice also had increased cortical insoluble Aβ40 (2.2-fold) and Aβ42 (1.5-fold), and soluble Aβ40 (1.8-fold) and Aβ42 (1.6-fold).
- Amyloid plaque load was increased in Abi3+/− and Abi3−/− cortices, and the number of Iba1+ cells around X34+ plaques was significantly decreased, while overall Iba1+ area did not differ.
- Transcriptomic analyses identified immune response as a top dysregulated pathway; C1qa, Ctss, complement genes, and other immune genes were up-regulated, and chemokines CCL24, CXCL10, CCL3, and CXCL16 were increased while CCL25 was decreased in Abi3−/− brains.
- Targeted scRNA-seq showed a marked microglial subpopulation shift: cluster 0 decreased from 38.34% in Abi3+/+ to 8.47% in Abi3−/−, while cluster 1 increased from 7.52% to 37.47%; cluster 1 was more DAM-like and immune-response enriched. LTP was significantly decreased in Abi3+/− and Abi3−/− mice compared with Abi3+/+.
Methods
- Abi3−/− mice were crossed with 5XFAD mice to generate 5XFAD;Abi3+/+, Abi3+/−, and Abi3−/− mice; both sexes were analyzed separately. Ages were 8 or 4.5 months for biochemical experiments, 6 months for electrophysiology, and 9 months for scRNA-seq.
- Main assays included Aβ electrochemiluminescence, immunohistochemistry (82E1, X34, Iba1), Western blot, qPCR, NanoString Mouse AD and Neuroinflammation panels, bulk RNA-seq, targeted scRNA-seq (BD Rhapsody Mouse Immune Response Panel, 397 genes), Bio-Plex chemokine assay, scratch-wound migration assay, phagocytosis assay, and hippocampal LTP recordings.
- Human ABI3 protein was analyzed using a Mount Sinai Brain Bank proteomics dataset from parahippocampal cortices of AD cases (N = 39) and cognitively normal controls (N = 23), with correction for cell-type composition.
Limitations
- The paper states that it cannot determine whether the inflammatory and microglial transcriptomic changes are direct consequences of Abi3 loss or secondary to increased Aβ pathology, and that deleting Abi3 before amyloid accumulation may not predict the effect of decreasing ABI3 after amyloid accumulation.
- The paper notes that the targeted scRNA-seq panel contains only 397 genes, so changes in other genes or cell types may have been missed; it also notes possible disruption of neighboring genes, especially Gngt2, by the Abi3 knockout strategy.
- The paper states that no good commercially available ABI3 antibody detects endogenous ABI3 protein, so deletion was confirmed by qPCR; the exact mechanism by which Abi3 regulates synaptic function was not identified.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures









Verification
Claims the paper makes
42 Valid · 2 Not valid · 7 Not checked · 125 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Recently, a large-scale human genetics study identified a rare coding variant in Abelson interactor family member 3 (ABI3) gene (rs616338, S209P, P = 4.56 × 10−10, odss ratio = 1.43), and this variant was associated with increased risk of late-onset AD (LOAD) (8).”
§ Deletion of Abi3 gene locus exacerbates neuropathological features of Alzheimer’s disease in a mouse model of Aβ amyloidosis > INTRODUCTION
What the sources say
- Partly supportedcites [8] 8. R. Sims, S. J. van der Lee, A. C. Naj, C. Bellenguez, N. Badarinarayan, J. Jakobsdottir, B. W. Kunkle, A. Boland, R. Raybould, J. C. Bis, E. R. Martin, B. Grenier-Boley, S. Heilmann-Heimbach, V. Chouraki, A. B. Kuzma, K. Sleegers, M. Vronskaya, A. Ruiz, R. R. Graham, R. Olaso, P. Hoffmann, M. L. Grove, B. N. Vardarajan, M. Hiltunen, M. M. Nothen, C. C. White, K. L. Hamilton-Nelson, J. Epelbaum, W. Maier, S. H. Choi, G. W. Beecham, C. Dulary, S. Herms, A. V. Smith, C. C. Funk, C. Derbois, A. J. Forstner, S. Ahmad, H. Li, D. Bacq, D. Harold, C. L. Satizabal, O. Valladares, A. Squassina, R. Th sourceExperimental — accuracy not yet measured
The paper’s Abstract identifies rs616338 in ABI3 as a rare coding variant associated with increased late-onset Alzheimer’s disease risk, with P=4.56×10−10 and OR=1.43. It identifies the protein change as p.S209F, not S209P as the citing sentence states. (LLM, conf=0.90)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Similar to newly identified other AD risk variants (e.g., TREM2, SPI1, and MS4A6A), ABI3 is highly expressed in microglia (8, 9, 11).”
§ Deletion of Abi3 gene locus exacerbates neuropathological features of Alzheimer’s disease in a mouse model of Aβ amyloidosis > INTRODUCTION
What the sources say
- Supportedcites [8] 8. R. Sims, S. J. van der Lee, A. C. Naj, C. Bellenguez, N. Badarinarayan, J. Jakobsdottir, B. W. Kunkle, A. Boland, R. Raybould, J. C. Bis, E. R. Martin, B. Grenier-Boley, S. Heilmann-Heimbach, V. Chouraki, A. B. Kuzma, K. Sleegers, M. Vronskaya, A. Ruiz, R. R. Graham, R. Olaso, P. Hoffmann, M. L. Grove, B. N. Vardarajan, M. Hiltunen, M. M. Nothen, C. C. White, K. L. Hamilton-Nelson, J. Epelbaum, W. Maier, S. H. Choi, G. W. Beecham, C. Dulary, S. Herms, A. V. Smith, C. C. Funk, C. Derbois, A. J. Forstner, S. Ahmad, H. Li, D. Bacq, D. Harold, C. L. Satizabal, O. Valladares, A. Squassina, R. Th source
The paper states that ABI3 has high expression in microglial cells and limited expression in other brain cell types. Its Online Methods also report higher ABI3 expression in purified cortical microglia/macrophages than in bulk cortex. Page numbers are not provided in our copy. (LLM, conf=0.94)
- Partly supportedcites [9] 9. O. J. Conway, M. M. Carrasquillo, X. Wang, J. M. Bredenberg, J. S. Reddy, S. L. Strickland, C. S. Younkin, J. D. Burgess, M. Allen, S. J. Lincoln, T. Nguyen, K. G. Malphrus, A. I. Soto, R. L. Walton, B. F. Boeve, R. C. Petersen, J. A. Lucas, T. J. Ferman, W. P. Cheshire, J. A. van Gerpen, R. J. Uitti, Z. K. Wszolek, O. A. Ross, D. W. Dickson, N. R. Graff-Radford, N. Ertekin-Taner, ABI3 and PLCG2 missense variants as risk factors for neurodegenerative diseases in Caucasians and African Americans. Mol. Neurodegener. 13, 53 (2018). 30326945 10.1186/s13024-018-0289-x PMC6190665 sourceExperimental — accuracy not yet measured
The Background identifies ABI3-expressing microglial clusters in AD brains, and the Discussion describes ABI3 as part of a co-expressed microglial gene network. The Results report higher expression of that network in AD temporal cortex, but do not establish that ABI3 itself is highly expressed in microglia generally. (LLM, conf=0.82)
- Supportedcites [11] 11. J. I. Satoh, Y. Kino, M. Yanaizu, Y. Tosaki, K. Sakai, T. Ishida, Y. Saito, Microglia express ABI3 in the brains of Alzheimer's disease and Nasu-Hakola disease. Intractable Rare Dis. Res. 6, 262– 268 (2017). 29259854 10.5582/irdr.2017.01073 PMC5735279 source
The Results (section 3) report intense ABI3 expression chiefly in a subset of microglia in the examined brains. The Discussion (section 4) likewise describes intense ABI3 immunoreactivity almost exclusively on a subset of microglia in normal-control, Alzheimer’s disease, and Nasu-Hakola disease brains. This supports the ABI3 portion of the citing sentence, with the qualification that the finding concerns a subset of microglia. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“We observed an increase in Serpina3n, a gene that is known to be associated with AD risk (30), in Abi3−/− mice.”
§ Deletion of Abi3 gene locus exacerbates neuropathological features of Alzheimer’s disease in a mouse model of Aβ amyloidosis > RESULTS > ABI3 regulates immune response
What the sources say
- Partly supportedcites [30] 30. Y. Harigaya, M. Shoji, T. Nakamura, E. Matsubara, K. Hosoda, S. Hirai, Alpha 1-antichymotrypsin level in cerebrospinal fluid is closely associated with late onset Alzheimer's disease. Intern. Med. 34, 481– 484 (1995). 7549128 10.2169/internalmedicine.34.481 sourceExperimental — accuracy not yet measured
The Results (page not provided) show that cerebrospinal-fluid alpha1-antichymotrypsin levels were elevated in patients with late-onset AD, supporting an association with AD. The paper does not identify Serpina3n or establish that the gene is associated with AD risk. The increase in Abi3−/− mice is the citing authors’ own observation, not a finding attributed to this source. (LLM, conf=0.82)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Because 5XFAD mice are known to have a sex-dependent difference in the extent of amyloid accumulation (25), we designed our study to consider sex difference, analyzing the results separately between male and female mice.”
§ Deletion of Abi3 gene locus exacerbates neuropathological features of Alzheimer’s disease in a mouse model of Aβ amyloidosis > RESULTS > Soluble and insoluble Aβ levels are increased in Abi3−/− mice
What the sources say
- Supportedcites [25] 25. K. R. Sadleir, W. A. Eimer, S. L. Cole, R. Vassar, Aβ reduction in BACE1 heterozygous null 5XFAD mice is associated with transgenic APP level. Mol. Neurodegener. 10, 1 (2015). 25567526 10.1186/1750-1326-10-1 PMC4297413 source
The Background states that female 5XFAD mice have higher Aβ42 levels and more amyloid plaques than males. The Results also report higher Aβ42 levels and plaque load in females, particularly in the 5XFAD/BACE1+/+ group. This supports the cited reason for analyzing males and females separately. (LLM, conf=0.94)
boostedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Because inflammatory proteins (e.g., interleukin-1β, tumor necrosis factor–α, and interferon-γ) can alter APP expression, APP processing, or Aβ transport (47–50), the inflammatory changes caused by the deletion of Abi3 locus may have contributed to the increase in APP protein level and subsequently Aβ accumulation.”
§ Deletion of Abi3 gene locus exacerbates neuropathological features of Alzheimer’s disease in a mouse model of Aβ amyloidosis > DISCUSSION
What the sources say
- Partly supportedcites [47] 47. M. Yamamoto, T. Kiyota, M. Horiba, J. L. Buescher, S. M. Walsh, H. E. Gendelman, T. Ikezu, Interferon-gamma and tumor necrosis factor-alpha regulate amyloid-beta plaque deposition and beta-secretase expression in Swedish mutant APP transgenic mice. Am. J. Pathol. 170, 680– 692 (2007). 17255335 10.2353/ajpath.2007.060378 PMC1851864 sourceExperimental — accuracy not yet measured
The Results section, “TNF-α Enhances Astrocyte BACE1 Expression and Aβ Production” (page unavailable), reports that TNF-α increased β-processing of APP; the Discussion also links IFN-γ to increased Aβ production through TNF-α. The paper does not substantively discuss an effect of interleukin-1β outside its reference list, so it supports the claim’s general point about inflammatory proteins and APP processing, but not all three examples attributed to it. (LLM, conf=0.82)
- Partly supportedcites [48] 48. L. N. Nilsson, K. R. Bales, G. DiCarlo, M. N. Gordon, D. Morgan, S. M. Paul, H. Potter, α-1-antichymotrypsin promotes beta-sheet amyloid plaque deposition in a transgenic mouse model of Alzheimer's disease. J. Neurosci. 21, 1444– 1451 (2001). 11222634 10.1523/JNEUROSCI.21-05-01444.2001 PMC6762932 sourceExperimental — accuracy not yet measured
The Discussion (page not provided) says IL-1 induces APP-mRNA translation and suggests that the inflammatory protein ACT may affect APP processing or, more likely, Aβ clearance. It does not specify IL-1β or establish the claimed effects for tumor necrosis factor-α or interferon-γ. (LLM, conf=0.85)
- Not checked — no full text of the sourcecites [49] 49. J. T. Rogers, L. M. Leiter, J. McPhee, C. M. Cahill, S. S. Zhan, H. Potter, L. N. Nilsson, Translation of the alzheimer amyloid precursor protein mRNA is up-regulated by interleukin-1 through 5′-Untranslated region sequences. J. Biol. Chem. 274, 6421– 6431 (1999). 10037734 10.1074/jbc.274.10.6421 source
- Supportedcites [50] 50. F. Alasmari, M. A. Alshammari, A. F. Alasmari, W. A. Alanazi, K. Alhazzani, Neuroinflammatory cytokines induce amyloid beta neurotoxicity through modulating amyloid precursor protein levels/metabolism. Biomed. Res. Int. 2018, 1– 8 (2018). 10.1155/2018/3087475 PMC6222241 30498753 source
Section 2.1 reports that IL-1β increases APP expression and that TNF-α and IFN-γ upregulate APP. Section 2.2 reports effects of these cytokines on APP-processing enzymes, while Section 1.1 suggests inflammatory cytokines may decrease Aβ transport into the vascular system. The cited claim does not attribute the separate inference about Abi3 deletion to this source. (LLM, conf=0.93)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
101 more claims · 5 with their cited sources checked
Create a free account to see all 176 claims and every source verdict.
- Probably not a substantial claim. 50
- It may state two separate claims as one. 30
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“as well as exacerbated microgliosis and astrogliosis in 5XFAD. 25 , 57”
From Unique transcriptomic alterations in 5XFAD;PS19 mouse model identify glial lipid dysregulation and coordinated microglial–oligodendrocyte responses (2026) · cites this paper as [57]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Karahan et al. demonstrated that genetically deleting Abi3, a protein essential for cytoskeletal dynamics, significantly impaired the migration and phagocytosis of microglia. 25”
From Deletion of miR-33, a regulator of the ABCA1–APOE pathway, ameliorates neuropathological phenotypes in APP/PS1 mice (2024) · cites this paper as [25]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“We demonstrated that the loss of ABI3 function dramatically increased Aβ accumulation and exacerbated neuroinflammation and synaptic dysfunction in these mice.”
From The effect of Abi3 locus deletion on the progression of Alzheimer’s disease-related pathologies (2023) · cites this paper as [22]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Consistent with this hypothesis, we detected fewer microglia around the plaques in the old cohort (22).”
From The effect of Abi3 locus deletion on the progression of Alzheimer’s disease-related pathologies (2023) · cites this paper as [22]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“our study has now demonstrated how deletion of Abi3 gene locus can have dramatic impacts on the seemingly distinct disease states of obesity and neurodegeneration, likely due to disruptions in microglia functions (Karahan et al., 2021).”
From Deletion of the Alzheimer’s disease risk gene Abi3 locus results in obesity and systemic metabolic disruption in mice (2022) · cites this paper as Karahan et al., 2021
Experimental — accuracy not yet measured
25 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Deletion of Abi3 gene locus exacerbates neuropathological features of Alzheimer’s disease in a mouse model of Aβ amyloidosis > RESULTS > Immune gene–targeted single-cell transcriptomic analysis identified distinct microglia subclusters in Abi3−/− mice
“Unsupervised clustering revealed 14 distinguished clusters across the samples (Fig. 8A).”
§ Deletion of Abi3 gene locus exacerbates neuropathological features of Alzheimer’s disease in a mouse model of Aβ amyloidosis > RESULTS > Immune gene–targeted single-cell transcriptomic analysis identified distinct microglia subclusters in Abi3−/− mice
“microglia (clusters 0 to 6 and 10), T cells (cluster 7), macrophages (clusters 8 and 9), neutrophils (cluster 12), and B cells (cluster 14) (Fig. 8A and table S5) (40, 41). Clusters 11 and 13 could not be assigned to any specific cell type”
Citations
Cites
Fiji: an open-source platform for biological-image analysis
Schindelin, J., Arganda-Carreras, I., Frise, E., Kaynig, V., Longair, M., Pietzsch, T., Preibisch, S., Rueden, C., Saalfeld, S., Schmid, B., et al. (2012) · Nature Methods · doi:10.1038/nmeth.2019 · Cited by 66,890 · cited 3×
“Staining was quantified in cortical region using Fiji (ImageJ, NIH) (69) and CellProfiler 3.1.9 (Broad Institute) (70).”
MethodInfluentialSTAR: ultrafast universal RNA-seq aligner
Dobin, A., Davis, C. A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., & Gingeras, T. R. (2013) · Bioinformatics · doi:10.1093/bioinformatics/bts635 · Cited by 51,709
HTSeq—a Python framework to work with high-throughput sequencing data
Anders, S., Pyl, P. T., & Huber, W. (2015) · Bioinformatics · doi:10.1093/bioinformatics/btu638 · Cited by 21,464
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Polazzi, E., Mengoni, I., Caprini, M., Peña-Altamira, E., Kurtys, E., & Monti, B. (2013) · Neurosignals · doi:10.1159/000337115 · Cited by 8,994
Spatial reconstruction of single-cell gene expression data
Satija, R., Farrell, J. A., Gennert, D., Schier, A. F., & Regev, A. (2015) · Nature Biotechnology · doi:10.1038/nbt.3192 · Cited by 7,055
A Unique Microglia Type Associated with Restricting Development of Alzheimer’s Disease
Keren-Shaul, H., Spinrad, A., Weiner, A., Matcovitch-Natan, O., Dvir-Szternfeld, R., Ulland, T. K., David, E., Baruch, K., Lara-Astaiso, D., Toth, B., et al. (2017) · Cell · doi:10.1016/j.cell.2017.05.018 · Cited by 5,493 · cited 4×
“DAM marker genes were initially identified in 5XFAD mice when 5XFAD mice were compared to wild-type mice (36).”
BackgroundMethodInfluentialAlzheimer's Disease Is a Synaptic Failure
Selkoe, D. J. (2002) · Science · doi:10.1126/science.1074069 · Cited by 4,420 · cited 1×
“It is considered an early time point molecular change that is followed by neuronal loss and cognitive deficits (1, 34).”
BackgroundMicroglia: Active sensor and versatile effector cells in the normal and pathologic brain
Hanisch, U.-K., & Kettenmann, H. (2007) · Nature Neuroscience · doi:10.1038/nn1997 · Cited by 3,676 · cited 1×
“Specifically, microglia can promote clearance of A through phagocytosis and regulate brain immunity by secreting inflammatory cytokines in AD (7).”
BackgroundOakley, H., Cole, S. L., Logan, S., Maus, E., Shao, P., Craft, J., Guillozet-Bongaarts, A., Ohno, M., Disterhoft, J., Van Eldik, L., et al. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.1202-06.2006 · Cited by 3,530 · cited 2×
“Animals 5XFAD mice (66) were purchased from the Jackson Laboratory [Mutant Mouse Resource & Research Centers (MMRRC) 34840, B6SJLTg(APPSwFlLon,PSEN1*M146L*L286V)6799Vas/ Mmjax)], and Abi3−/− mice were obtained from the MMRRC, University of California, Davis, Mouse Biology Program [C57BL/6N-Abi3tm1.”
Method
Cited by
Alzheimer’s Disease: An Updated Overview of Its Genetics
Andrade-Guerrero, J., Santiago-Balmaseda, A., Jeronimo-Aguilar, P., Vargas-Rodríguez, I., Cadena-Suárez, A. R., Sánchez-Garibay, C., Pozo-Molina, G., Méndez-Catalá, C. F., Cardenas-Aguayo, M.-D.-C., Diaz-Cintra, S., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043754 · Cited by 336
Microglial efferocytosis: Diving into the Alzheimer’s disease gene pool
Romero-Molina, C., Garretti, F., Andrews, S. J., Marcora, E., & Goate, A. M. (2022) · Neuron · doi:10.1016/j.neuron.2022.10.015 · Cited by 111
Modeling late-onset Alzheimer’s disease neuropathology via direct neuronal reprogramming
Sun, Z., Kwon, J.-S., Ren, Y., Chen, S., Walker, C. K., Lu, X., Cates, K., Karahan, H., Sviben, S., Fitzpatrick, J. A. J., et al. (2024) · Science · doi:10.1126/science.adl2992 · Cited by 96
Self-citationXu, Y., Au, N. P. B., & Ma, C. H. E. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.896852 · Cited by 70
WASP family proteins: Molecular mechanisms and implications in human disease
Kramer, D. A., Piper, H. K., & Chen, B. (2022) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2022.151244 · Cited by 57
“…was further confirmed by a recent mouse model, in which knocking out Abi3 disrupted microglia migration and phagocytosis, D.A. Kramer et al. increased amyloid β (A β ) accumulation, decreased microglia clustering around the A β plaques, and impaired long-term potentiation (Karahan et al., 2021).”
Background
Metadata
- Authors
- Karahan, H., Smith, D. C., Kim, B., Dabin, L. C., Al-Amin, M. M., Wijeratne, H. R. S., Pennington, T., Viana di Prisco, G., McCord, B., Lin, P. B.-C., Li, Y., Peng, J., Oblak, A. L., Chu, S., Atwood, B. K., & Kim, J.
- Affiliations
- Indiana University Indianapolis (US)
- Stark Neurosciences Research Institute, Indiana University School of Medicine, Indianapolis, IN 46202, USA.
- St. Jude Children's Research Hospital (US)
- Corresponding author
- Kim, Jungsu
- ORCID
- Venue
- Science Advances
- Published
- 2021-11-05
- Volume
- 7
- Issue
- 45
- Pages
- eabe3954-eabe3954
- ISSN
- 2375-2548 (ISSN-L)
- PMC
- PMC8565913
- OpenAlex
- W3208723974
- Cited by
- 53
- References
- 82
- Citations by year
- 2026: 9 · 2025: 12 · 2024: 11 · 2023: 11 · 2022: 9 · 2021: 1
- FWCI
- 5.02
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- Locations
- Science Advances (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- IUScholarWorks (Indiana University) (submittedVersion, cc-by)
- Funders
- Eli Lilly and Company
- Lilly Endowment
- National Institutes of Health
- School of Medicine, Indiana University
- National Institute on Aging (R01AG054102, R01AG053500, R01AG053242, R21AG050804)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- ABI3, Alzheimer's disease, microglia, neuroinflammation, amyloid-beta deposition, gene deletion, mouse model, phagocytosis, microglial migration
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-17, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-17 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.